ABSTRACT
Trichophyton tonsurans is an uncommon cause of tinea corporis, and an even more uncommon cause of Majocchi's granuloma. We report a patient who developed tinea corporis with Majocchi's granuloma from T. tonsurans infection. Immunocompromised hosts are predisposed to develop cutaneous fungal infections, as was the case with this patient. Majocchi's granuloma is a rare complication with immunosuppression, but is significant to consider when a fungal infection is suspected because it may require more aggressive therapy.
Subject(s)
Granuloma/microbiology , Immunocompromised Host , Kidney Transplantation , Tinea Favosa/microbiology , Trichophyton/isolation & purification , Administration, Oral , Adult , Antifungal Agents/therapeutic use , Drug Administration Schedule , Granuloma/complications , Granuloma/drug therapy , Griseofulvin/therapeutic use , Humans , Ketoconazole/therapeutic use , Male , Tinea Favosa/complications , Tinea Favosa/drug therapy , Treatment Outcome , Trichophyton/drug effectsABSTRACT
A 25-year-old female patient from Kosovo presented with a slowly progressive cicatricial alopecia which had started when she was 6 years old. Her brother in Kosovo had similar lesions. At the erythematous border of the hairless area, crusts, erosions and pustules were apparent. Mycological examination identified Trichophyton schönleinii, the causative pathogen of favus. Histological examination revealed hyphae and showed no features suggestive of other causes of cicatricial alopecia. Systemic terbinafine combined with topical ciclopiroxolamine resulted in rapid improvement of this disease which is seldom seen in Central Europe.
Subject(s)
Alopecia/etiology , Alopecia/pathology , Cicatrix/diagnosis , Cicatrix/etiology , Tinea Favosa/complications , Tinea Favosa/diagnosis , Adult , Chronic Disease , Female , Humans , Tinea Favosa/microbiologySubject(s)
Alopecia/etiology , Ectodermal Dysplasia/complications , Tinea Capitis/complications , Tinea Favosa/complications , Adolescent , Alopecia/congenital , Child , Child, Preschool , Female , Humans , Infant , MaleABSTRACT
A total of 247 patients with tinea capitis were divided into two groups and treated with griseofulvin in two different ways: the first group received the drug every other day, and the second received it twice a week. The dosage was 5 mg/lb, with a maximum of 1 gm/day in both cases. In the first group, 99 percent of the patients were completely cured within seven weeks. Of those who received the griseofulvin twice a week, 91 percent were completely cleared within eight weeks. None of those in either group showed any signs of side effects from the medication.
